Citi’s 16th Annual BioPharma Conference on
September 8, 2021
Morgan Stanley 19th Annual Global Healthcare
Conference on September 9, 2021 at 5:00 pm ET
2021 Wells Fargo Virtual Healthcare Conference
on September 10, 2021 at 1:20 pm ET
HC Wainwright 23rd Annual Global Investment
Conference on September 13, 2021 at 7:00 am ET
SVB Leerink CybeRx Series: Neuromuscular, Rare
Diseases & Genetic Medicines on September 23, 2021
2021 Cantor Virtual Global Healthcare
Conference on September 27, 2021 at 8:00 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
the following investor healthcare conferences: Citi’s 16th Annual
BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare
Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC
Wainwright 23rd Annual Global Investment Conference and the 2021
Cantor Virtual Global Healthcare Conference and the SVB Leerink
CybeRx Series.
Conferences Details:
Event:
Citi’s 16th Annual BioPharma
Conference
Date:
Wednesday September 8, 2021
Format:
1x1 meetings
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Kimberly Lee, SVP, Corporate
Communications and Investor Relations
Event:
Morgan Stanley 19th Annual Global
Healthcare Conference
Date:
Thursday September 9, 2021
Time:
5:00 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
2021 Wells Fargo Virtual Healthcare
Conference
Date:
Friday September 10, 2021
Time:
1:20 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
HC Wainwright 23rd Annual Global
Investment Conference
Date:
Monday September 13, 2021
Time:
7:00 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
SVB Leerink CybeRx Series: Neuromuscular,
Rare Diseases & Genetic Medicine
Date:
Thursday September 23, 2021
Format:
1x1 meetings
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Kimberly Lee, SVP, Corporate
Communications and Investor Relations
Event:
2021 Cantor Virtual Global Healthcare
Conference
Date:
Monday September 27, 2021
Time:
8:00 am ET
Format:
Fireside Chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024